newsfilter
← Latest News
GlobeNewswire·

Kaplan Fox Alerts Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to an Ongoing Investigation of Possible Securities Law Violations

  • Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • Madrigal filed its Form 10-Q on November 3, 2026, revealing a whistleblower complaint filed by a former employee on October 9, 2026.
  • The complaint, filed in the United States District Court for the Northern District of Illinois, alleges retaliation under the Sarbanes-Oxley Act of 2002 regarding internal concerns about data & reporting practices.
  • The former employee resigned in January 2026 & the company disputes the allegations & plans to vigorously defend itself.
  • Madrigal stock price declined 8.08% following the news, dropping from $431.16 on November 2, 2026, to $396.32 on November 3, 2026.
  • Kaplan Fox & Kilsheimer LLP is a national law firm with over 50 years of experience in securities litigation & has recovered more than $10 billion for clients.
  • Investors may contact the firm via email at jcampisi@kaplanfox.com or by phone at (212) 329-8571 to discuss potential claims.
  • Contacting the firm does not create an attorney-client relationship & past results do not guarantee future outcomes.
Company
Kaplan Fox & Kilsheimer, LLP
Keywords
Kaplan Fox & Kilsheimer, LLP, MDGL Investor Alert, MDGL Investigation, NASDAQ: MDGL, $MDGL, Shareholder Alert, Securities Investigation, Kaplan Fox, Class Action